StemCyte-KY enters 2026 with significant momentum. The company has passed the Taiwan Stock Exchange (TWSE) listing review and expects to go public in the first half of the year. Furthermore, its multi-ethnic umbilical cord blood (UCB) public bank collection program has secured extended U.S. government subsidies through 2027, while its Long-COVID therapeutic, REGENECYTE, is projected to generate revenue starting in Q2.

• Clinical Validation: Phase II clinical results for REGENECYTE in Post-COVID Syndrome were recently published in eClinicalMedicine (Part of The Lancet discovery science, IF=10). The study demonstrated excellent safety and significant improvement in patient fatigue by week 6 (p < 0.001$), with sustained efficacy through week 26 (p < 0.01$).
• Commercial Innovation: REGENECYTE has been granted an Expanded Access Program (EAP) by the U.S. FDA, allowing for commercial use prior to full Biologics License Application (BLA) approval. Pricing has been set at $9,052.66 per dose in California and $11,223.82 in Florida. This "revenue before listing" model allows the company to collect Real-World Evidence (RWE) during its upcoming Phase III trials.
• Strategic Position: As the only Asian private cell therapy company consistently involved in U.S. federal cord blood programs, StemCyte is leveraging NIH’s $1.8 billion RECOVER initiative to address a global Long-COVID market estimated to impact 400 million people annually.

Resource: 永笙拚上半年掛牌